Biodesix Announces First Quarter 2025 Results and Highlights

About this update from Biodesix, Inc.

[{"type":"image","alt":"Biodesix, Inc.","displaySize":"","headline":null,"caption":"Biodesix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/cd1b6f0f04b27dd51e3e0af52fefc5f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZXm0WIRUy_.i8bpwMH7VDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cd1b6f0f04b27dd51e3e0af52fefc5f0","width":300,"height":110}},"lazy":false},{"type":"text","content":"Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024;","length":72,"tagName":"p"},{"type":"text","content":"Gross margins of 79.4% for Q1 2025;","length":35,"tagName":"p"},{"type":"text","content":"Q1 2025 Net loss improved by 18% compared to Q1 2024;","length":53,"tagName":"p"},{"type":"text","content":"Updated 2025 Revenue Guidance to a range of $80-85 million; ","length":59,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Today at 4:30 p.m. ET","length":49,"tagName":"p"},{"type":"text","content":"LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025.","length":218,"tagName":"p"},{"type":"text","content":"“Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline,” said Scott Hutton, Chief Executive Officer. “Year-over-year, we grew revenue by 21%, powered by growth in both our lung diagnostic testing and diagnostic services, all while decreasing our SG&A spend. Lung Diagnostics revenue grew 18%, which is the 16th straight quarter of greater than 15% growth. We also increased our already strong gross margins to 79.4%, improved Net Loss by 18% and Adjusted EBITDA by 11% on our path to profitability, and presented multiple studies on our pipeline products to help facilitate future growth.”","length":729,"tagName":"p"},{"type":"text","content":"“In the second half of 2024, we conducted a commercial pilot to explore the expansion of our commercial reach to include pulmonology and the select primary care physicians in their referral network. The goal of the pilot was to assess our ability ...

More updates from Biodesix, Inc.